[China-Indonesia News] Hong Kong-Invested Enterprises Expand into Indonesia’s GPU Computing Power Market

I. Hong Kong-Invested Enterprises’ Deployment in Indonesia’s GPU Computing Power Market

China Hong Kong–based Zhihang Group recently issued an announcement stating that it has entered into a high-performance computing services leasing agreement with Multipolar. Under the terms of the agreement, Zhihang Group will provide GPU-based HPC services in Indonesia on a trading basis, while Multipolar Group will act as a distributor, procuring these services from Zhihang Group and reselling them to its end customers in Indonesia.

Multipolar is a company listed on the Indonesia Stock Exchange (stock code: MLPT) and part of the Lippo Group. It is a leading local provider of information technology infrastructure, cloud computing, hybrid data center services, data analytics, cybersecurity, and artificial intelligence solutions. The company has long collaborated with global institutions to drive digital transformation across sectors such as healthcare, education, finance, and real estate in Indonesia, and boasts well-established market channels and a robust customer base.

In its interim report for the period ended September 30, 2025, Zhihang Group disclosed that, given the high power consumption associated with its high-performance computing business, the Group has partnered with an AI data center on energy-efficiency initiatives. This strategic collaboration has enabled the Group to accumulate experience and resources in penetrating the AI computing market, while also underscoring the substantial market potential and growth opportunities in this sector. The present cooperation agreement was reached through fair and mutually beneficial negotiations and will be implemented on standard commercial terms.

Zhihang Group plans to deliver its services through a trade-based model and is currently in discussions with NVIDIA Cloud Partners (NCP) and relevant industry experts on procurement arrangements to enable the distribution of these services to Multipolar. At the same time, Zhihang Group and Multipolar will also provide localized support to suppliers, including assistance in identifying suitable B300 data center sites that offer adequate power supply and comply with applicable standards.

Under the agreement, ZhiXing Group will enter Indonesia’s computing power market on a light-asset basis, without incurring any capital expenditures while providing high-performance computing services to Multipolar.

Source: Daily Indonesia

II. Hengbo Shares Plans to Invest Approximately VND 86.1 Billion to Acquire a 75% Stake in an Indonesian Auto Parts Company

According to the announcement, GENERAL EXCELLENCE TECHNOLOGY LIMITED (Hong Kong), a wholly owned subsidiary of Hengbo Shares, plans to acquire a 75% equity interest in PT Optima Elektronik Manufaktur (PT OEM) in Indonesia using its own or self-raised funds, with a transaction value of IDR 86.118 billion, equivalent to approximately RMB 35.7128 million.

Hengbo Co., Ltd. stated that the primary objective of this acquisition is to enter the automotive instrument cluster market and, leveraging the target company’s localized R&D and manufacturing capabilities in Indonesia, achieve synergistic development with its existing smart motorcycle instrument cluster business.
By integrating PT OEM’s distribution channels and customer base, the company is poised to further expand the range of product applications, extend the value chain, and enhance its overall competitiveness in the Southeast Asian market.

In addition, the agreement stipulates that the target company must be integrated into PT Toyota Astra Motor’s supplier network within one year and achieve actual sales within three years, thereby further strengthening its business ties with the Indonesian OEM.

Source: Port of Departure
 

III. Total Investment Increased to RMB 1.477 Billion as Zhonghong Medical Bolsters Its Nitrile Glove Project in Indonesia
 

On March 25, Zhonghong Pulin Medical Supplies Co., Ltd. issued an announcement stating that it has increased the total investment for Phase I of its nitrile glove production base in Indonesia from RMB 1.092 billion to RMB 1.477 billion, with a primary focus on upgrading the automation and digital intelligence of its production lines to further enhance its competitiveness in the international market.
According to the announcement, Zhonghong Medical plans to increase the total investment for Phase I of its Indonesian production base—specifically the project to build 20 nitrile glove production lines—from the originally planned RMB 1.092 billion to RMB 1.477 billion, representing an increase of 35.26%.

The core driver of this investment increase is the upgrade of production lines. The company stated that the additional capital expenditure is primarily directed toward automated control systems, intelligent equipment, and supporting infrastructure, with an incremental outlay of approximately RMB 380 million. Meanwhile, as production-line standards are raised, civil-engineering costs have increased by about RMB 94 million compared with the original plan. Although certain land-related expenses have declined, the overall impact has nonetheless pushed up the project’s total investment.
The company believes that its Indonesian base enjoys advantages in rubber raw materials, energy costs, and localized production, and that, when combined with advanced digital and intelligent management capabilities, these factors will help enhance overall cost control and product quality stability.

From a regional perspective, Indonesia boasts both abundant raw-material resources and a strategic geographic location, making it a crucial hub for connecting European and American markets with emerging markets. As global supply chains undergo restructuring, Southeast Asia is increasingly becoming a priority destination for Chinese medical consumables and manufacturing firms seeking to expand overseas.

Source: Port of Departure

IV. Chinese Pharmaceutical Companies Enter the Indonesian Pharmaceutical Market

Guangdong Taienkang Pharmaceutical recently announced that its core product, “Aitingjiu” dapoxetine hydrochloride tablets, has successfully obtained registration approval from Indonesia’s National Agency of Drug and Food Control (BPOM). This milestone not only marks the company’s first-ever overseas registration for a core product but also makes the drug Indonesia’s first generic version of this class, signaling the official launch of the company’s commercialization efforts in the Southeast Asian market. Dapoxetine hydrochloride is the first-line treatment recommended in both domestic and international guidelines for the diagnosis and management of premature ejaculation, offering significant clinical benefits, a low safety risk, and rapid onset of action. The drug was independently developed by the company and officially launched in the Chinese domestic market in August 2020. Currently, it maintains a leading position in China’s over-the-counter dapoxetine hydrochloride market, particularly in the offline retail segment, where it has established a strong brand advantage—laying a solid foundation for its future expansion into international markets.

To advance its market presence in Indonesia, Tainkang has previously reached a letter of intent and entered into an agency agreement with PT ANVITA PHARMA INDONESIA (hereinafter referred to as “ANVITA”), a leading biopharmaceutical company in Indonesia. ANVITA specializes in the R&D and manufacturing of high-end small-molecule APIs as well as CDMO services, operates a GMP-certified production facility in Indonesia, and has already commercialized more than ten products, thereby providing robust support for the marketing and promotion of “Aitingjiu” in the Indonesian market. As the world’s fourth most populous country with a population exceeding 270 million, Indonesia is one of the largest and fastest-growing pharmaceutical markets in Southeast Asia. Benefiting from national healthcare initiatives, substantial unmet clinical needs, and favorable policy reforms, Indonesia’s pharmaceutical market reached US$11 billion in 2023, with a compound annual growth rate of 10%, and is projected to surpass US$15 billion by 2025.

Meanwhile, Indonesia is China’s largest trading partner for pharmaceutical imports and exports within ASEAN in 2024, with bilateral pharmaceutical trade posting a compound annual growth rate of 12% over the past five years. The launch of “Aitingjiu” as the first generic product is expected to leverage its first-mover advantage and capture a significant share of the market. In addition to “Aitingjiu,” Taencon’s “Aitinglie” finasteride–tadalafil capsules, “Aitingwei” tadalafil tablets, and “Aitingda” sildenafil citrate orally disintegrating tablets have all entered into agency agreements with ANVITA. Under these agreements, ANVITA will place orders upon receipt of Indonesian marketing authorization for the respective products; specifically, the minimum total annual order value for finasteride–tadalafil capsules over the first three years amounts to USD 10.3154 million. Taencon has already initiated the overseas registration process for this product, aiming to realize order-based revenue at the earliest possible date.

In addition, the company’s international expansion has now extended to multiple countries, with several of its products having entered into agency or distribution agreements with pharmaceutical distributors in Malaysia, Nigeria, Saudi Arabia, and other markets. The successful registration of “Aitingjiu” in Indonesia represents a substantive breakthrough in Taienkang’s global strategy. Moving forward, the company will leverage ANVITA’s local resources to steadily advance the commercialization of its products, further expand its presence in emerging Southeast Asian markets, and capitalize on the region’s growth momentum to unlock new avenues for expansion.

Source: Daily Indonesia

V. Hong Kong-Invested Injection Molding Machine Companies Expand into the Indonesian Market

Zhenxiong Group, a leading manufacturer of injection molding machines, recently announced that its Indonesian subsidiary and technical service center in Semarang, Central Java, have officially commenced operations. This milestone marks the entry of the group’s localization strategy—after more than five decades of deep engagement in the Southeast Asian market—into a new phase, under which it will provide more comprehensive and integrated solutions to injection-molding manufacturers in Indonesia and neighboring countries.

The newly commissioned Indonesian Technical Service Center offers a wide range of integrated services, including technical support, specialized training, parts supply, after-sales maintenance, and spare-parts warehousing. Upon completion, it will significantly enhance the production efficiency and operational reliability of local industries in the region.

Through this center, the company has achieved true localization of its services, enabling Indonesian customers to obtain faster access to original-equipment manufacturer technical support and a steady supply of standard spare parts, thereby effectively reducing response times and further enhancing its market competitiveness. Centered in Central Java, the new service center provides effective coverage of surrounding industrial hubs, with operations spanning multiple application areas such as food packaging, home-appliance components, and everyday consumer goods. It offers tailored technical consulting, equipment-upgrade solutions, and standardized operational training to diverse customer segments. At the same time, the center will actively promote smart-industry solutions, helping local manufacturers advance their digital and green transformations and driving the industry’s evolution from traditional manufacturing toward high-quality production.

For many years, the company has placed great emphasis on collaborating with local distributors and building a robust service network, thereby establishing a strong reputation and capturing a significant market share in Indonesia. The official launch of the subsidiary and the technical service center underscores the group’s long-term commitment to and unwavering confidence in the Indonesian market. Moving forward, the group will leverage a more efficient, locally tailored service model to work closely with regional customers in seizing opportunities presented by industrial upgrading, while continuing to deepen its presence and drive growth in Indonesia and the broader Southeast Asian market.

Source: Daily Indonesia

Editor: Zhu Rencheng

Proofread by: Li Jifeng

Reviewed by: Wei Shenghua

Submission Email | ygdwxcb@163.com